FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis?

FDA-Approved Antiparasitic Drugs in the 21st Century: A Success for Helminthiasis?

Diseases caused by helminth infections affect more than a quarter of the population of the world, but the therapeutic arsenal is limited. The approval of moxidectin in 2018 and triclabendazole in 2019 by the FDA marked an important moment in the fight against diseases of poverty, such as helminthias...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Trends in parasitology 2020-07, Vol.36 (7), p.573-575
Hauptverfasser: de Moraes, Josué, Geary, Timothy G.
Format: Artikel
Sprache:eng
Schlagworte:
FDA
helminthiasis
moxidectin
triclabendazole
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Diseases caused by helminth infections affect more than a quarter of the population of the world, but the therapeutic arsenal is limited. The approval of moxidectin in 2018 and triclabendazole in 2019 by the FDA marked an important moment in the fight against diseases of poverty, such as helminthiases.
ISSN:1471-4922
1471-5007
DOI:10.1016/j.pt.2020.04.005